Ratings by B.Riley (Chad Mabry)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/16/2025 | MediciNova | MNOV | Maintain | Buy (N/A) |
|
Details | ||
| 5/24/2022 | INmune Bio Inc. | INMB | Downgrade | Neutral (Buy) |
7.27 (1.33) |
-81.71% | Details | |
| 4/5/2022 | Curis | CRIS | Maintain | Buy (N/A) |
|
Details | ||
| 1/24/2022 | Vor Biopharma, Inc. | VOR | Maintain | Buy (N/A) |
|
Details | ||
| 1/24/2022 | MediciNova | MNOV | Maintain | Buy (N/A) |
|
Details | ||
| 1/24/2022 | INmune Bio Inc. | INMB | Maintain | Buy (N/A) |
|
Details | ||
| 1/24/2022 | GT Biopharma Inc. | GTBP | Maintain | Buy (N/A) |
|
Details | ||
| 9/7/2021 | INmune Bio Inc. | INMB | Maintain | Buy (N/A) |
|
Details | ||
| 7/14/2021 | INmune Bio Inc. | INMB | Maintain | Buy (N/A) |
|
Details | ||
| 6/24/2021 | GT Biopharma Inc. | GTBP | Maintain | Buy (N/A) |
|
Details | ||
| 4/21/2021 | INmune Bio Inc. | INMB | New Coverage | Buy (N/A) |
11.37 (1.33) |
-88.3% | Details | |
| 4/13/2021 | GT Biopharma Inc. | GTBP | New Coverage | Buy (N/A) |
10.44 (0.47) |
-95.5% | Details | |
| 3/25/2021 | Curis | CRIS | New Coverage | Buy (N/A) |
11.46 (0.99) |
-91.36% | Details | |
| 3/25/2021 | Vor Biopharma, Inc. | VOR | New Coverage | Buy (N/A) |
41.79 (15.12) |
-63.82% | Details | |
| 1/15/2021 | BioVie Inc. | BIVI | New Coverage | Buy (N/A) |
27.91 (1.36) |
-95.13% | Details | |
| 12/7/2020 | TFF Parmaceuticals | TFFP | New Coverage | Buy (N/A) |
15.80 (0.07) |
-99.56% | Details | |
| 11/12/2020 | Altimmune | ALT | Maintain | Buy (N/A) |
|
Details | ||
| 9/25/2020 | Altimmune | ALT | New Coverage | Buy (N/A) |
12.53 (3.54) |
-71.75% | Details | |
| 9/25/2020 | Axcella Health Inc. | AXLA | New Coverage | Buy (N/A) |
4.29 (4.58) |
6.76% | Details | |
| 7/13/2020 | Alcobra Ltd. | ADHD | New Coverage | Buy (N/A) |
1.40 (1.46) |
4.29% | Details | |
| 7/13/2020 | Arcturus Therapeutics | ARCT | New Coverage | Buy (N/A) |
48.62 (62.27) |
28.07% | Details | |
| 7/13/2020 | Vaxart Inc. | VXRT | New Coverage | Buy (N/A) |
8.19 (8.73) |
6.59% | Details | |
| 7/6/2020 | Acasti Pharma | ACST | Upgrade | Buy (Neutral) |
0.53 (0.71) |
33.96% | Details | |
| 2/26/2020 | NGM Biopharmaceuticals | NGM | Maintain | Buy (N/A) |
|
Details | ||
| 1/31/2020 | Durect Corp | DRRX | New Coverage | Buy (N/A) |
2.12 (1.91) |
-9.91% | Details | |
| 1/21/2020 | Novavax | NVAX | Maintain | Buy (N/A) |
|
Details | ||
| 12/30/2019 | Spring Bank Pharmaceuticals | SBPH | Downgrade | Neutral (Buy) |
1.26 (1.21) |
-3.97% | Details | |
| 12/18/2019 | Fortress Biotech | FBIO | New Coverage | Buy (N/A) |
1.95 (3.34) |
71.28% | Details | |
| 12/5/2019 | X4 Pharmaceuticals | XFOR | New Coverage | Buy (N/A) |
10.08 (3.76) |
-62.7% | Details | |
| 11/27/2019 | Novavax | NVAX | New Coverage | Buy (N/A) |
3.78 (9.98) |
164.02% | Details | |
| 10/17/2019 | NGM Biopharmaceuticals | NGM | New Coverage | Buy (N/A) |
9.97 (1.54) |
-84.55% | Details | |
| 3/25/2019 | MediciNova | MNOV | New Coverage | Buy (N/A) |
8.68 (1.36) |
-84.33% | Details | |
| 3/19/2019 | Akari Therapeutics | AKTX | Maintain | Buy (N/A) |
|
Details | ||
| 1/4/2019 | Akari Therapeutics | AKTX | New Coverage | Buy (Neutral) |
1.66 (0.25) |
-84.94% | Details |
